Influenza A Infections Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen R&D, Ainos, Genentech, TaiGen Biotechnology

Posted on
by

Influenza A Infections Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen R&D, Ainos, Genentech, TaiGen Biotechnology
The Key Influenza A Infections Companies in the market include – Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen Research & Development, LLC, Ainos, Inc., Genentech, Inc., TaiGen Biotechnology Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., and others .

 

The Influenza A Infections market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Influenza A Infections pipeline products will significantly revolutionize the Influenza A Infections market dynamics.

 

DelveInsight’s “Influenza A Infections Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Influenza A Infections, historical and forecasted epidemiology as well as the Influenza A Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Get a Free sample for the Influenza A Infections Market Report

https://www.delveinsight.com/sample-request/influenza-a-infections-market

 

Some of the key facts of the Influenza A Infections Market Report:

  • The Influenza A market size was valued at nearly USD 5 billion in 2025 and is expected to reach approximately USD 10 billion by 2036, registering a CAGR of 7.9% during the forecast period from 2026 to 2036.

  • In February 2026, Cidara Therapeutics announced MK-1406 (CD388) is currently being evaluated in the Phase 3 ANCHOR study (NCT07159763).

  • In January 2026, Merck announced The company has successfully completed a cash tender offer, conducted via its subsidiary, for the acquisition of all outstanding common shares of Cidara Therapeutics.

  • In March 2026, Cocrystalpharma announced The company plan to continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A with an additional Phase 2a study.

  • In February 2026, The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation for mCombriax, a vaccine developed by Moderna, for the prevention of influenza disease.

  • In March 2025, Cidara Therapeutics announced two upcoming presentations on CD388 in Influenza at the 38th International Conference on Antiviral Research (ICAR).

  • In April 2025, Roche announced that New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza showing a reduction in the transmission of influenza viruses.

  • In the United States, the vaccinated population was highest among adults aged 18–49 years, while the lowest vaccination uptake was observed in pregnant women in 2025; overall, the vaccinated pool was segmented across children (0–4, 5–12 years), adolescents (13–17 years), adults (18–49, 50–64, ≥65 years), and pregnant women.

  • In 2025, the influenza vaccine failure rate in the United States was estimated to be approximately 70%, indicating a substantial proportion of vaccinated individuals remained susceptible to infection.

  • By conducting secondary analysis of publicly available surveillance data In Japan, it was observed that in Japan according to the Ministry of Health, Labour and Welfare, the average approximately 196,895 weekly influenza cases were reported in November 2025, corresponding to an average of 51.12 cases per medical institution, indicating high epidemic intensity

  • In Europe, influenza A (H1N1)pdm09 emerged as the predominant subtype in 2024, accounting for approximately 57–93% of all influenza A cases, as reported by the European Respiratory Virus Surveillance Summary (ERVISS) (2025).

  • In the United States, the total number of influenza A positive cases is projected to increase over the study period from 2022 to 2036, reflecting a rising disease burden over time.

  • Key Influenza A Infections Companies: Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen Research & Development, LLC, Ainos, Inc., Genentech, Inc., TaiGen Biotechnology Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., and others

  • Key Influenza A Infections Therapies: XOFLUZA (baloxavir marboxil), RAPIVAB (peramivir), FLUAD QUADRIVALENT, Ingavirin, Neumifil, mRNA-1010, JNJ-63623872, Oseltamivir, MHAA4549A, TG-1000, Zanamivir, and others

 

Influenza A Infections Overview

Influenza A infections are caused by the influenza A virus, a highly contagious respiratory pathogen responsible for seasonal flu epidemics and occasional pandemics. It infects the nose, throat, and lungs, leading to symptoms such as fever, cough, sore throat, body aches, and fatigue. Severe cases can result in complications like pneumonia, particularly in young children, the elderly, and individuals with weakened immune systems.

 

To Know in detail about the Influenza A Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Influenza A Infections Market Insights

 

Influenza A Infections Epidemiology Segmentation:

The Influenza A Infections market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalence of Influenza A Infections

  • Prevalent Cases of Influenza A Infections by severity

  • Gender-specific Prevalence of Influenza A Infections

  • Diagnosed Cases of Episodic and Chronic Influenza A Infections

 

Download the report to understand which factors are driving Influenza A Infections epidemiology trends @ Influenza A Infections Epidemiological Insights

 

Influenza A Infections Market

The dynamics of the Influenza A Infections market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2022-2036.

 

Influenza A Infections Therapies and Key Companies

  • XOFLUZA (baloxavir marboxil): Roche and Shionogi

  • CC-42344: Cocrystal Pharma

  • CD388: Cidara Therapeutics

  • mRNA-1010: Moderna

  • Flu Pandemic mRNA (GSK4382276A): GlaxoSmithKline

  • RAPIVAB (peramivir): BioCryst Pharmaceuticals

  • FLUAD QUADRIVALENT: Seqirus

  • Ingavirin: Valenta Pharm JSC

  • Neumifil: Pneumagen

  • mRNA-1010: ModernaTX

  • JNJ-63623872: Janssen Research & Development, LLC

  • Oseltamivir: Ainos, Inc.

  • MHAA4549A: Genentech, Inc.

  • TG-1000: TaiGen Biotechnology Co., Ltd.

  • Zanamivir: Jiangsu Simcere Pharmaceutical Co., Ltd.

 

To know more about Influenza A Infections treatment, visit @ Influenza A Infections Medications

 

Influenza A Infections Market Strengths

  • The rising prevalence of Influenza is the major factors driving the growth of the treatment market

  • The presence of a large number of manufacturers is further boosting the growth of the treatment market

 

Influenza A Infections Market Barriers

  • Influenza A Infections key players are heavily investing in research activities to expand the therapeutic application for treatment drugs which in turn are creating more scopes and opportunities for the growth of Influenza A Infections treatment market

 

Scope of the Influenza A Infections Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Influenza A Infections Companies: Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen Research & Development, LLC, Ainos, Inc., Genentech, Inc., TaiGen Biotechnology Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., and others

  • Key Influenza A Infections Therapies: XOFLUZA (baloxavir marboxil), RAPIVAB (peramivir), FLUAD QUADRIVALENT, Ingavirin, Neumifil, mRNA-1010, JNJ-63623872, Oseltamivir, MHAA4549A, TG-1000, Zanamivir, and others

  • Influenza A Infections Therapeutic Assessment: Influenza A Infections current marketed and Influenza A Infections emerging therapies

  • Influenza A Infections Market Dynamics: Influenza A Infections market drivers and Influenza A Infections market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Influenza A Infections Unmet Needs, KOL’s views, Analyst’s views, Influenza A Infections Market Access and Reimbursement

 

Discover more about therapies set to grab major Influenza A Infections market share @ Influenza A Infections Treatment Landscape

 

Table of Contents

1. Influenza A Infections Market Report Introduction

2. Executive Summary for Influenza A Infections

3. SWOT analysis of Influenza A Infections

4. Influenza A Infections Patient Share (%) Overview at a Glance

5. Influenza A Infections Market Overview at a Glance

6. Influenza A Infections Disease Background and Overview

7. Influenza A Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Influenza A Infections

9. Influenza A Infections Current Treatment and Medical Practices

10. Influenza A Infections Unmet Needs

11. Influenza A Infections Emerging Therapies

12. Influenza A Infections Market Outlook

13. Country-Wise Influenza A Infections Market Analysis (2022–2036)

14. Influenza A Infections Market Access and Reimbursement of Therapies

15. Influenza A Infections Market Drivers

16. Influenza A Infections Market Barriers

17. Influenza A Infections Appendix

18. Influenza A Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/